NCT01013974 - A Study of GSK573719 in Healthy Japanese Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2009

Primary Completion Date

December 18, 2009

Study Completion Date

December 18, 2009

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK573719 250 μg

Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.

DRUG

GSK573719 500 μg

Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.

DRUG

GSK573719 1000 μg

Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.

DRUG

GSK573719 matching Placebo

Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.

Trial Locations (1)

890-0081

GSK Investigational Site, Kagoshima